Tamtam Try Tamtam free
Medtronic logo

Medtronic account plan

Healthcare technology innovation

At a glance

Medtronic is an Ireland-incorporated medical device maker selling in 150+ countries: $36,364 million FY2026 net sales and over 95,000 employees.

Medtronic plc, founded in 1949, incorporated in Ireland and run operationally from the Minneapolis, Minnesota area, develops and sells device-based medical therapies to hospitals, ambulatory surgical centers, physician offices and alternate care sites in more than 150 countries, through direct sales representatives and distributors. In fiscal 2026 (ended April 24, 2026) net sales were $36,364 million (+8%), split almost evenly between the U.S. ($18,103 million) and international markets ($18,261 million), with GAAP net income attributable to Medtronic of $4,801 million and free cash flow of $5,426 million. It has over 95,000 full-time employees, 43% of them in the U.S. or Puerto Rico. Geoffrey S. Martha is Chairman and CEO; the diabetes business, MiniMed Group, listed on Nasdaq in March 2026 and remains about 90% owned pending full separation.

Business units

Strategic priorities

Innovation-driven growth platforms
Growth is led by Cardiac Ablation Solutions (past $2 billion of trailing twelve-month revenue), Symplicity renal denervation, Hugo robotics, Altaviva and Stealth AXiS, alongside the foundational CRM, spine and surgical businesses.
Data, AI and automation
One of three strategic areas in the FY2026 10-K is to "Turn data, AI, and automation into action", tailoring therapies in real time and supporting remote monitoring and care delivery.
Margin expansion and cost-out
The CFO's priorities are "Portfolio simplification, SKU rationalization, cost-out and broader supply-chain initiatives"; more than 9,000 SKUs were rationalized and FY27 operating profit is expected to grow about 10%.
Complete the MiniMed separation
Medtronic intends to close the Diabetes separation before fiscal year-end to "create two focused companies"; related restructuring is expected to cost $300 million to $500 million pre-tax through fiscal year 2029.
Tuck-in M&A and venture investments
Recent acquisitions (CathWorks, Scientia Vascular, SPR Therapeutics) should add over $150 million of inorganic growth in FY27, and 16 venture investments were made in FY26.

Latest results

In Q1 fiscal 2027 (three months ended July 31, 2026), net sales rose 14% to $9,756 million from $8,578 million, with organic growth of 13.7%; an extra selling week added about $570 million. Cardiovascular grew 20% to $3,927 million, led by Electrophysiology Therapies (+30%), Neuroscience 10% and Medical Surgical 10%. Non-GAAP EPS was $1.45 against $1.26, and free cash flow was $1,290 million against $584 million. Management raised FY27 guidance to organic growth of 7.25% to 7.75% and EPS of $5.94 to $6.00, and guided Q2 to roughly 6% organic growth.

Investments and deals

CathWorks
Acquired April 20, 2026 for $525 million of consideration, including $115 million contingent, adding FFRangio to coronary.
Scientia Vascular
Closed June 12, 2026 for $681 million of total consideration, including $123 million contingent, adding neurovascular access products to Specialty Therapies.
SPR Therapeutics
Closed July 16, 2026 for $654 million, adding temporary peripheral nerve stimulation to Neuromodulation.
Robotics partnerships
A strategic investment and distribution agreement for Cornerstone Robotics' Sentire Surgical System in select markets outside the U.S., alongside Hugo, which should pass 50,000 completed procedures by year-end.
Capex and buybacks
FY2026 capex was $1,904 million; 10 million shares were repurchased at an average of $93.25 in FY2026, and the quarterly dividend rose to $0.72.

Challenges and risks

Tariffs and trade policy
Medtronic estimates a tariff cost of about $250 million in FY27; IEEPA tariff refunds are being processed after the Supreme Court ruling of February 20, 2026.
Pricing pressure and China tenders
Price-sensitive hospitals, GPOs and volume-based procurement tenders in China weigh on pricing.
Bariatric volumes and GLP-1 drugs
Advanced stapling declined on shifts to robotic surgery and lower bariatric volumes, and the 10-K names GLP-1 drug makers as competitors; the Medical Surgical unit's fair value exceeded carrying value by only about 12%.
Regulatory, quality and supply
Risks include FDA and EU MDR approvals, recalls such as Pipeline Vantage, sole-source components and constrained sterilization capacity.
Separation execution
The MiniMed separation carries execution risk, with a Transition Services Agreement of up to 24 months.

What leadership says

“We are executing, and this quarter's results are a clear proof point.”

Geoff Martha, Chairman and Chief Executive Officer · Q1 FY27 earnings commentary, 2026-09-01

“laser-focused on translating stronger growth and enhanced efficiency into durable earnings leverage”

Thierry Piéton, EVP and Chief Financial Officer · Q1 FY27 earnings commentary, 2026-09-01

“MedTech is structurally resilient because the fundamentals are durable”

Geoff Martha, Chairman and Chief Executive Officer · Q4 FY26 earnings commentary, 2026-06-03

Where a supplier can help

Supply-chain and SKU simplification
Tied to the margin expansion and cost-out priority: supply-chain, procurement and portfolio-analytics suppliers supporting SKU rationalization and cost-down.
Data and AI in care delivery
Tied to the data, AI and automation priority: software, data and remote-monitoring partners for real-time therapy tailoring.
Separation and integration services
Tied to the MiniMed separation and the CathWorks, Scientia and SPR acquisitions: IT carve-out, transition services and integration support.
Commercial scale-up of growth platforms
Tied to Cardiac Ablation, Symplicity and Altaviva growth: physician training, referral and market-access tools as installed bases and procedure volumes expand.
Tariff and trade compliance
Tied to the tariff challenge: customs, sourcing and trade-compliance services as Medtronic manages about $250 million of FY27 tariff cost.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Medtronic?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Medtronic

What does Medtronic do?

Medtronic develops, manufactures and sells device-based medical therapies, from pacemakers and ablation systems to spine robotics and surgical staplers, to healthcare providers in more than 150 countries.

What is Medtronic's revenue?

Net sales were $36,364 million in fiscal 2026 (ended April 24, 2026), up 8%. In Q1 fiscal 2027 net sales were $9,756 million.

How many employees does Medtronic have?

Medtronic has over 95,000 full-time employees, 43% of them in the U.S. or Puerto Rico.

Who leads Medtronic?

Geoffrey S. Martha is Chairman and CEO, and Thierry Piéton is EVP and CFO.

What is Medtronic's strategy?

Accelerating innovation-driven growth through platforms such as pulsed field ablation, renal denervation and robotics, turning data and AI into action, cutting costs and separating its diabetes business.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)